Final survival results for the LURET phase II study of vandetanib in previously treated patients with RET-rearranged advanced non-small cell lung cancer
Lung Cancer(2021)
摘要
•RET fusion is a key oncogenic alteration in non-small cell lung cancer.•Vandetanib is an oral multikinase inhibitors with RET kinase activity.•Vandetanib has a clinically meaningful efficacy for RET-rearranged lung cancer.•Multikinase inhibitors lead to off-target adverse events not related to RET.•RET-selective inhibitors have improved efficacy and favorable toxicity profile.
更多查看译文
关键词
RET,Non-small cell lung cancer,Vandetanib,Phase II
AI 理解论文
溯源树
样例
![](https://originalfileserver.aminer.cn/sys/aminer/pubs/mrt_preview.jpeg)
生成溯源树,研究论文发展脉络
Chat Paper
正在生成论文摘要